About: Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 August 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2000 (uk) article scientifique publié en 2000 (fr) im August 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 2000 (ast) scientific article published on 01 August 2000 (en)
publication date	wds:Q74107594-57308262-791D-4A4F-8483-7461BA0FDC66
publication date	2000-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74107594-D2D4011F-A9A6-4491-85DB-5B929BF0AD9B
language of work or name	English
cites work	wds:Q74107594-242B4A38-A523-47E4-9E3F-FD8210FAE683 wds:Q74107594-45C6BFCA-8070-481C-8673-53635AC4E275 wds:Q74107594-5292EF29-1E66-432F-95A1-E60FFFD9BD59 wds:Q74107594-90773C85-712A-4961-AA52-800A03ACC8CC wds:Q74107594-9D930C2A-796A-4FDB-B99B-CD81E3D47490 wds:Q74107594-F80DE68A-6678-4F36-83FC-CC57D1DF4455
cites work	Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32
author name string	wds:Q74107594-0A4BA841-2F6D-48D1-977B-5013CF4A424E wds:Q74107594-1A5A5060-4FEB-4644-8EB1-58AC65ADBB14 wds:Q74107594-29DA4B59-6908-4AD1-9EE7-5DF0B5A7000A wds:Q74107594-36B4DAEB-1F71-4A2A-9591-D55B4013BA12 wds:Q74107594-446D6938-558C-4297-B5C2-F024056ABD1C wds:Q74107594-4DA58BF6-EC88-41FF-BB02-6C3A893C7819 wds:Q74107594-53B1264E-0B51-48AC-8340-F32F91089296 wds:Q74107594-805AF073-9177-4879-8112-B125D2411640 wds:Q74107594-A28A37BA-4C64-45B5-92A5-22B6B5A6B15C
author name string	R Bahnson R E Greenberg A L Patterson Z Wajsman M Israel D Webber T Sweatman J Gulfo L Weems
rdfs:label	Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (en) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (nl)
skos:prefLabel	Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (en) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (nl)
name	Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (en) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (nl)
title	wds:Q74107594-6EFC58F3-BC39-41E5-B8E0-274DF0DD5A8C
title	Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer (en)
page(s)	wds:Q74107594-C4CF3960-2E11-4944-BFED-4C8E1883772B
page(s)	232-235
instance of	wds:Q74107594-DE4A6129-3180-4D0C-A06C-60D01CFFCFD2
instance of	scholarly article
PubMed ID	wds:Q74107594-DA7C8766-9409-4357-82EE-D8A090B9FDF4
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10925084
PubMed ID	10925084
published in	wds:Q74107594-85B3FFF1-8B5F-435C-9A39-6B1FB2BA3EEB
published in	Urology
issue	wds:Q74107594-8622A6B0-EA50-4C3B-B4D2-7D9F399698D6
volume	wds:Q74107594-EC5FBECD-6C28-4FFC-A03A-AFE8B41A6ED7
issue	2
volume	56
DOI	wds:Q74107594-41BB0B12-0E23-4271-80A1-590B9125B238
DOI	http://dx.doi.org/10.1016/S0090-4295(00)00654-3
DOI	10.1016/S0090-4295(00)00654-3
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74107594
is cites work of	New agents for bacillus Calmette-Guérin-refractory bladder cancer Intravesical treatments of bladder cancer: review. Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group Intravesical therapy for urothelial carcinoma of the bladder Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model Pharmacoepidemiology and drug safety Intravesical therapy of superficial bladder cancer Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study Side effects of perioperative intravesical treatment and treatment strategies for these side effects Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
is cites work of	wds:Q37911278-34955EF1-F6B7-48CC-BA18-7D6D90E93838 wds:Q73839673-0CCFEA36-41FF-493F-825C-5F6DDDE27E52 wds:Q73755473-3A2098B8-C4E6-4E40-B558-F7196F308505 wds:Q39801337-4451C2AA-E177-4A81-91E9-D94C2B58D634 wds:Q38009095-E5A5C7D8-9550-46F5-AD64-6749C999ED2A wds:Q37283563-CFB3C4A1-6A42-4913-99BA-55ED6327882C wds:Q86507878-100122FA-E784-4390-8804-49EAC174714E wds:Q86507881-8A31E809-5E24-4329-8ACB-616F59DDB555 wds:Q46162263-2EE029A4-12BE-4416-B020-D14E504DEB90 wds:Q36738254-BC441477-71A3-49AC-9D3C-F1D05F713B0F wds:Q37221184-AD4A792C-840C-4812-BE58-B1177D9DC9B5 wds:Q36784305-C4E64B49-F658-4DD6-AEFD-DA1FD2568978 wds:Q38078886-8AAD6983-F9EA-4D8B-BA6E-645FEF4D3F04 wds:Q41905201-0252DF96-126D-4905-9B08-0631FD27A9BC

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software